NCCN Pfizer and Astellas Enzalutamide Request for Proposals (RFP) Announcement

Funding Agency:
National Comprehensive Cancer Network

National Comprehensive Cancer Network® (NCCN®) is pleased to announce a collaboration with Pfizer Global Medical Grants (Pfizer) and Astellas Pharma, Inc. (Astellas) to offer a new grant opportunity.  This grant will promote the advancement of scientific knowledge concerning the mechanisms of actions, underlying biology, and clinical effectiveness of enzalutamide in prostate cancer.

The overall aim is to develop innovative, novel, and impactful studies that address unmet needs as well as support the design and performance of enzalutamide research in the treatment of prostate cancer. Clinical trials, prospective studies, and retrospective correlative studies of enzalutamide treatment trials or datasets are encouraged. Studies with correlative endpoints will be accepted, and studies that retrospectively analyze biomarkers (tissue, liquid biopsy, and other assays) within prospective trials or datasets will be accepted. It is hoped Letters of Intent (LOI) submitted in response to this RFP will be useful in guiding further development of enzalutamide in combination with other therapies.

 LOIs are due by 5:00 pm ET, Friday, May 14, 2021.  Please direct questions regarding this RFP to Nicole Kamienski at kamienski@nccn.org with the subject line, “Enzalutamide 2021 Project.”

RFP

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science

External Deadline

May 14, 2021